Clinical Trial Update: High-dose Antioxidants for Central Serous Chorioretinopathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose antioxidants for Central Serous Chorioretinopathy has completed; the update does not specify results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• High-dose Antioxidants

Snippet

Sponsor: Prince of Songkla University | Conditions: Central Serous Chorioretinopathy | Phase 2 | Status: COMPLETED